Metabolic control of T cell immune response through glycans in inflammatory bowel disease
Ana M Dias,Alexandra Correia,Márcia S Pereira,Catarina R Almeida,Inês Alves,Vanda Pinto,Telmo A Catarino,Nuno Mendes,Magdalena Leander,M Teresa Oliva-Teles,Luís Maia,Cristina Delerue-Matos,Naoyuki Taniguchi,Margarida Lima,Isabel Pedroto,Ricardo Marcos-Pinto,Paula Lago,Celso A Reis,Manuel Vilanova,Salomé S Pinho
DOI: https://doi.org/10.1073/pnas.1720409115
2018-05-15
Abstract:Mucosal T lymphocytes from patients with ulcerative colitis (UC) were previously shown to display a deficiency in branched N-glycosylation associated with disease severity. However, whether this glycosylation pathway shapes the course of the T cell response constituting a targeted-specific mechanism in UC remains largely unknown. In this study, we demonstrated that metabolic supplementation of ex vivo mucosal T cells from patients with active UC with N-acetylglucosamine (GlcNAc) resulted in enhancement of branched N-glycosylation in the T cell receptor (TCR), leading to suppression of T cell growth, inhibition of the T helper 1 (Th1)/Th17 immune response, and controlled T cell activity. We further demonstrated that mouse models displaying a deficiency in the branched N-glycosylation pathway (MGAT5-/-, MGAT5+/-) exhibited increased susceptibility to severe forms of colitis and early-onset disease. Importantly, the treatment of these mice with GlcNAc reduced disease severity and suppressed disease progression due to a controlled T cell-mediated immune response at the intestinal mucosa. In conclusion, our human ex vivo and preclinical results demonstrate the targeted-specific immunomodulatory properties of this simple glycan, proposing a therapeutic approach for patients with UC.